BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, February 9, 2026
Home
»
Newsletters
» BioWorld
BioWorld
March 4, 2010
View Archived Issues
After Trauma, Mitochondrial DNA Set Off Sepsis-Like Response
Read More
Ataluren's DMD Expedition Hits Bump with Failed Phase IIb Trial
Read More
NiCox, Bausch & Lomb Ink $179.5M Deal in Glaucoma
Read More
Clinic Roundup
Read More
Stock Movers for March 4, 2010
Read More
Other News To Note
Read More
Financings Roundup
Read More
Medivation Rocked by Dimebon Miss in Late-Stage AD Study
Shares in Medivation Inc. fell 67.5 percent Wednesday on news that its Phase III trials of Alzheimer's drug candidate Dimebon missed all of the study's stated goals, smashing some high hopes on Wall Street. (BioWorld Today)
Read More
ExonHit Emerges a Winner in Allergan, BMS Pain Deal
Read More
